Press by Brain Navi Biotechnology
NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan’s Food and Drug Administration (TFDA) in July 2022, and is planned for submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022.
The NaoTrac human trials were performed at the reputable Hualien Tzu-Chi Medical Center, with the External Ventricular Drain (EVD) placement abstract results published in the well-known European journal Acta Neurochirurgica. Dr. Tsung-Lang, Chiu stated, “The results of this report show that the average time spent on the patient registration was 1423.8 seconds. The mean target deviation was 1.68mm, and the mean angular deviation was 1.99 degrees, all within the accepted tolerance for minimal tissue damage.” Dr. Chiu concluded, “NaoTrac has several advantages besides the high precision, like a non-invasive, non-contact patient registration process with a fast and accurate procedure, the system provides precise navigation to the surgical target. It’s also user-friendly, and has many other benefits.”
NaoTrac’s technology, Surface Mapping Auto-Registration Technology (SMART), merges machine vision, robotics, and A.I. to streamline surgical procedures with real-time imaging and minimal invasive outcomes. NaoTrac will be used for other surgeries like endoscopic brain surgery, cell implantation, and other operations. Brain Navi is attending the CNS Annual Meeting held in San Francisco, and the Taiwan Expo USA 2022 in Washington D.C., both in October, to showcase NaoTrac and the release of the neurosurgical endoscope.
For more information please visit: brainnavi.com